Latest Breaking News On - Wei li - Page 6 : comparemela.com

'Set the Alarm' Rings Across Asia Desks on Double-Whammy Fed Day

'Set the Alarm' Rings Across Asia Desks on Double-Whammy Fed Day
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Mizuho
Hokkaido
Japan
Taiwan
Melbourne
Victoria
Australia
Singapore
Sydney
New-south-wales
India
Tokyo

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company…

China
Tongji
Sichuan
Suzhou
Jiangsu
Rhui-zhou
Guangdong
United-states
Hong-kong
Shanghai
Taiwan
Macau

Innovent Announces Data From Pivotal Phase 2 TRUST-I Study Of Taletrectinib(ROS1 Inhibitor) Are Published In The JCO And Reported At 2024 ASCO Annual ...

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceut

Rhui-zhou
Guangdong
China
Tongji
Sichuan
Suzhou
Jiangsu
Shanghai
Hong-kong
Taiwan
Macau
United-states

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Tongji
Sichuan
China
Shanghai
Wei-li
Thoracic-cancer-institute
Tongji-university-school-of-medicine
Medical-oncology
Shanghai-pulmonary-hospital
Tongji-university-school
Drug-evaluation
National-medical-products-administration

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Macau
Tongji
Sichuan
China
Chicago
Illinois
United-states
San-francisco
California
Hong-kong
New-york
Taiwan